Back to search
Locally Advanced or Metastatic and Unresectable HCC
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced or Metastatic and Unresectable HCC trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Locally Advanced or Metastatic and Unresectable HCC trials you may qualify forThe primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single age…
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment…
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy…
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients…
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor an…
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alon…
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommende…
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial